Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

934 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Residual masses after chemotherapy for metastatic testicular cancer: the clinical implications of the association between retroperitoneal and pulmonary histology. Re-analysis of Histology in Testicular Cancer (ReHiT) Study Group.
Steyerberg EW, Donohue JP, Gerl A, Toner GC, Schraffordt Koops H, Fosså SD, Keizer HJ. Steyerberg EW, et al. Among authors: fossa sd. J Urol. 1997 Aug;158(2):474-8. doi: 10.1016/s0022-5347(01)64506-3. J Urol. 1997. PMID: 9224327 Review.
Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups.
Steyerberg EW, Keizer HJ, Fosså SD, Sleijfer DT, Toner GC, Schraffordt Koops H, Mulders PF, Messemer JE, Ney K, Donohue JP, et al. Steyerberg EW, et al. Among authors: fossa sd. J Clin Oncol. 1995 May;13(5):1177-87. doi: 10.1200/JCO.1995.13.5.1177. J Clin Oncol. 1995. PMID: 7537801 Free article.
Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.
Horwich A, Sleijfer DT, Fosså SD, Kaye SB, Oliver RT, Cullen MH, Mead GM, de Wit R, de Mulder PH, Dearnaley DP, Cook PA, Sylvester RJ, Stenning SP. Horwich A, et al. Among authors: fossa sd. J Clin Oncol. 1997 May;15(5):1844-52. doi: 10.1200/JCO.1997.15.5.1844. J Clin Oncol. 1997. PMID: 9164194 Free article. Clinical Trial.
Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council.
de Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, Fosså SD, Cook P, de Prijck L, Stenning S, Collette L. de Wit R, et al. Among authors: fossa sd. J Clin Oncol. 2001 Mar 15;19(6):1629-40. doi: 10.1200/JCO.2001.19.6.1629. J Clin Oncol. 2001. PMID: 11250991 Clinical Trial.
Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.
Fosså SD, Kaye SB, Mead GM, Cullen M, de Wit R, Bodrogi I, van Groeningen CJ, De Mulder PH, Stenning S, Lallemand E, De Prijck L, Collette L. Fosså SD, et al. J Clin Oncol. 1998 Feb;16(2):716-24. doi: 10.1200/JCO.1998.16.2.716. J Clin Oncol. 1998. PMID: 9469362 Clinical Trial.
934 results